Introduction
Myeloid cell leukemia 1 (Mcl-1) is an anti-apoptotic protein which is overexpressed in various leukemia and other cancers [1] . Mcl-1 has a very short half-life [2] , which has been suggested as a molecular mechanism for cells to switch into either the survival or apoptotic pathways in response to different stresses [3] . Recently, it has been demonstrated that downregulation of Mcl-1 by various pharmacological agents or genetic approaches dramatically increases ABT-737 lethality in various malignant cell types [4] . Different strategies for targeting Mcl-1 include (i) small interfering RNA [5] (ii) small-molecule inhibitors [6] and (iii) peptide inhibitors [7] . In recent years, therapeutic vaccination with synthetic peptides derived from anti-apoptotic proteins such as Mcl-1 has emerged as a promising strategy against hematological cancers.
In this study, 34 overlapping 20-mer peptides, spanning the entire Mcl-1 protein, were adjuvanted with cationic liposomes [8] 
Results and Discussion
The peptides were synthesized by Fmoc SPPS on a TentaGel S Ram Resin. Each amino acid was coupled in 3-fold excess using HATU, HOAt and DIEA (1:1:1.5) in DMF. Deprotection of the Fmoc group was effected by 20% piperidine in DMF. Following synthesis the peptides were cleaved from the resin for 2h using reagent TFA/TIS/DTT/H2O (88:2:5:5). The products were then purified by preparative RP-HPLC and characterized by MALDI-TOF-MS. and FvB mice.
Ir re le v a n t P r o te in /C A F 0 1 (Figure 2a ). These responses were also both seen in CB6F1 mice, suggesting they are H-2b restricted. Notably, although several additional peptides were predicted to contain H-2k binding peptides, none of these were found to be empirically immunogenic in our experiments. In FvB (H-2q) mice, Mcl_32 was uniquely immunogenic (Figure 2b) , while Mcl_25 and Mcl_27 peptides displayed MHC haplotype immunogenic promiscuity.
In conclusion, we found that the ensemble of overlapping Mcl-1 peptides (Figure 3 ) contained many immunogenic MHC II-restricted peptides. Future experiments to confirm that these CD4+ T cells induced against novel epitopes can recognize Mcl-1 over-expressing cells and enhance anti-tumor immunity in vivo will be important to determine whether such responses are indeed effective in tumor control.
